GOSSAMER BIO STOCK DROPS 78% FOLLOWING FAILURE OF LUNG CONDITION DRUG IN LATE-STAGE TRIAL
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy GOSS?
Source: moomoo
- Stock Performance: Gossamer Bio's shares plummeted by 78% following disappointing results from a late-stage trial of its drug candidate.
- Trial Outcome: The drug failed to meet its primary endpoint, leading to significant concerns about the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.555
Low
10.00
Averages
12.33
High
15.00
Current: 0.555
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in Oversold Healthcare Stocks
- Gossamer Bio Performance Review: On February 23, Gossamer Bio announced topline results from the PROSERA Phase 3 study, indicating the drug's activity in pulmonary arterial hypertension patients despite narrowly missing the statistical threshold, resulting in a 76% stock drop over the past month, with an RSI of 26.3 indicating oversold conditions.
- Brainsway Clinical Data: On March 4, Brainsway disclosed new clinical data showing a significantly faster, non-invasive treatment for depression, with a 52-week low of $3.92 and an RSI of 19.1, suggesting its stock is also oversold.
- Definitive Healthcare Earnings: Definitive Healthcare posted inline Q4 earnings on February 26, with CEO Kevin Coop highlighting progress across strategic pillars, despite a 38% stock drop in the past month and an RSI of 28.1, indicating potential for a rebound.
- Market Trend Analysis: Benzinga Pro signals indicate potential breakout opportunities for both Gossamer Bio and Definitive Healthcare, with respective stock gains of 23.4% and 5.2% on Wednesday, providing investors with signals to explore opportunities in oversold healthcare stocks.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: In the healthcare sector, Gossamer Bio Inc, Brainsway Ltd, and Definitive Healthcare Corp have relative strength indices (RSI) near or below 30, indicating these stocks are significantly undervalued and may present buying opportunities for investors.
- RSI Indicator Interpretation: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance, particularly in oversold conditions.
- Market Opportunity Analysis: According to Benzinga Pro, assets are typically considered oversold when the RSI is below 30, providing investors with opportunities to identify potential rebound stocks within the healthcare sector that could yield substantial returns.
- Investment Strategy Recommendations: Investors should focus on the fundamentals and market dynamics of these oversold stocks to make informed investment decisions at the right time, thereby capitalizing on profit opportunities arising from market fluctuations.
See More
Gossamer Bio's Phase 3 Trial Misses Key Endpoint
- Trial Failure: Gossamer Bio's Phase 3 PROSERA trial missed its primary endpoint, resulting in a more than 60% drop in stock value, indicating extreme market pessimism regarding the company's future prospects.
- Guidance Misstep: CEO Faheem Hasnain's May 2025 statement anticipated results in February 2026 but failed to disclose that the trial's statistical significance threshold was set at 0.025, significantly higher than the conventional 0.05, leading to a mismatch between investor expectations and actual risk.
- Investor Confidence Eroded: The lack of transparency regarding the statistical hurdle left investors relying on management's forward-looking statements unable to assess the risk of a technical miss, potentially resulting in substantial financial losses.
- Potential Legal Action: Affected investors are encouraged to contact legal counsel to discuss their rights, highlighting increasing market scrutiny on corporate governance and disclosure practices.
See More
Gossamer Bio Under Investigation After 80.1% Stock Plunge Following Trial Failure
- Legal Investigation Initiated: The Schall Law Firm has announced an investigation into Gossamer Bio, focusing on potential violations of securities laws, particularly regarding the issuance of false or misleading statements that could affect investor decisions.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its product candidate seralutinib failed to meet its primary endpoint in the Phase 3 PROSERA trial, leading to a significant loss of market confidence.
- Stock Price Plunge: Following this announcement, Gossamer's shares plummeted by over 80.1% on the same day, severely impacting shareholder investment value and potentially triggering further legal actions.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for discussions on protecting their rights, demonstrating the firm's commitment to supporting investor interests.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Gossamer Bio Under Investigation After 80% Stock Plunge
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Gossamer Bio and its executives have engaged in securities fraud or other unlawful business practices, raising serious concerns about corporate governance and compliance.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, directly impacting investor confidence.
- Stock Price Plunge: Following the trial results, Gossamer's stock price fell by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting market pessimism regarding the company's future prospects.
- Investor Alert: Pomerantz LLP advises investors to contact their attorneys for more information, indicating that the firm is actively seeking to provide legal support for affected investors, potentially leading to more class action lawsuits.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Gossamer Bio Performance Review: On February 23, Gossamer Bio announced topline results from the PROSERA Phase 3 study, indicating the drug's activity in pulmonary arterial hypertension patients despite narrowly missing the statistical threshold, resulting in a 76% stock drop over the past month, with an RSI of 26.3 indicating oversold conditions.
- Brainsway Clinical Data: On March 4, Brainsway disclosed new clinical data showing a significantly faster, non-invasive treatment for depression, with a 52-week low of $3.92 and an RSI of 19.1, suggesting its stock is also oversold.
- Definitive Healthcare Earnings: Definitive Healthcare posted inline Q4 earnings on February 26, with CEO Kevin Coop highlighting progress across strategic pillars, despite a 38% stock drop in the past month and an RSI of 28.1, indicating potential for a rebound.
- Market Trend Analysis: Benzinga Pro signals indicate potential breakout opportunities for both Gossamer Bio and Definitive Healthcare, with respective stock gains of 23.4% and 5.2% on Wednesday, providing investors with signals to explore opportunities in oversold healthcare stocks.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: In the healthcare sector, Gossamer Bio Inc, Brainsway Ltd, and Definitive Healthcare Corp have relative strength indices (RSI) near or below 30, indicating these stocks are significantly undervalued and may present buying opportunities for investors.
- RSI Indicator Interpretation: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance, particularly in oversold conditions.
- Market Opportunity Analysis: According to Benzinga Pro, assets are typically considered oversold when the RSI is below 30, providing investors with opportunities to identify potential rebound stocks within the healthcare sector that could yield substantial returns.
- Investment Strategy Recommendations: Investors should focus on the fundamentals and market dynamics of these oversold stocks to make informed investment decisions at the right time, thereby capitalizing on profit opportunities arising from market fluctuations.
See More
Gossamer Bio's Phase 3 Trial Misses Key Endpoint
- Trial Failure: Gossamer Bio's Phase 3 PROSERA trial missed its primary endpoint, resulting in a more than 60% drop in stock value, indicating extreme market pessimism regarding the company's future prospects.
- Guidance Misstep: CEO Faheem Hasnain's May 2025 statement anticipated results in February 2026 but failed to disclose that the trial's statistical significance threshold was set at 0.025, significantly higher than the conventional 0.05, leading to a mismatch between investor expectations and actual risk.
- Investor Confidence Eroded: The lack of transparency regarding the statistical hurdle left investors relying on management's forward-looking statements unable to assess the risk of a technical miss, potentially resulting in substantial financial losses.
- Potential Legal Action: Affected investors are encouraged to contact legal counsel to discuss their rights, highlighting increasing market scrutiny on corporate governance and disclosure practices.
See More
Gossamer Bio Under Investigation After 80.1% Stock Plunge Following Trial Failure
- Legal Investigation Initiated: The Schall Law Firm has announced an investigation into Gossamer Bio, focusing on potential violations of securities laws, particularly regarding the issuance of false or misleading statements that could affect investor decisions.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its product candidate seralutinib failed to meet its primary endpoint in the Phase 3 PROSERA trial, leading to a significant loss of market confidence.
- Stock Price Plunge: Following this announcement, Gossamer's shares plummeted by over 80.1% on the same day, severely impacting shareholder investment value and potentially triggering further legal actions.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for discussions on protecting their rights, demonstrating the firm's commitment to supporting investor interests.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Gossamer Bio Under Investigation After 80% Stock Plunge
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Gossamer Bio and its executives have engaged in securities fraud or other unlawful business practices, raising serious concerns about corporate governance and compliance.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, directly impacting investor confidence.
- Stock Price Plunge: Following the trial results, Gossamer's stock price fell by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting market pessimism regarding the company's future prospects.
- Investor Alert: Pomerantz LLP advises investors to contact their attorneys for more information, indicating that the firm is actively seeking to provide legal support for affected investors, potentially leading to more class action lawsuits.
See More
